BioCryst Pharmaceuticals, Inc.
BioCryst develops oral small-molecule and protein therapeutics for rare diseases. It markets peramivir injection under RAPIVAB, RAPIACTA, and PERAMIFLU names to treat acute uncomplicated influenza. ORLADEYO treats hereditary angioedema. The company also develops BCX10013, an oral factor D inhibitor for complement-mediated diseases. BioCryst has collaborations with various companies and institutions. Founded in 1986, the company is headquartered in Durham, North Carolina.
Overview
Strengths
- Current Price to Earnings Ratio (7.26) is lower than the sector mean (289.29).
- The company has low debt. Net Debt to EBITDA Ratio is 0.96 and it is lower than the sector mean.
- The company has high returns. ROIC (100.00%) is higher than the sector mean (14.71%).
- EV/EBITDA (6.20) is lower than the sector mean (51.86).
- EV/EBIT (6.54) is lower than the sector mean.
- Price to free cash flow (5.55) is lower than the sector mean.
- Strong EBITDA Margin of 41.74%.
Weaknesses
- With a depreciation Potential of -26.91%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
Key Financial Data